



Neuren (NEU) - ASX Announcement

17 December 2018

Larry Glass to retire as a director and continue as Chief Science Officer

Melbourne, Australia, 17 December 2018: Neuren Pharmaceuticals (ASX: NEU) today reported that Larry Glass will retire from the Neuren board of directors on 31 December 2018. Larry will continue in his executive role as Neuren's Chief Science Officer.

Neuren's Executive Chairman Richard Treagus commented: "In July 2018 we strengthened and refreshed the board through the appointment of 3 non-executive directors. That now enables Larry to retire as a director and focus on his important executive role as we advance the development of NNZ-2591 and approach the start of the trofinetide Phase 3 trial. On behalf of the board, I wish to acknowledge and thank Larry for his dedication and invaluable contribution as a director these last 6 years."

Larry Glass commented: "I have very much enjoyed my tenure as a director and appreciate having had the opportunity to play a role in the development and maturation of the company. I look forward to continuing to contribute as Chief Science Officer as we enter yet another exciting phase and pursue the opportunities that lie ahead."

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for neurodevelopmental and neurodegenerative disorders and brain injury. Neuren has completed Phase 2 development of trofinetide for Rett syndrome and has completed a Phase 2 clinical trial in Fragile X syndrome. The programs in Rett syndrome and Fragile X syndrome have each been granted Fast Track designation by the US Food and Drug Administration and Orphan Drug designation in both the United States and the European Union. Neuren has granted an exclusive license to ACADIA Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, whilst retaining all rights to trofinetide outside North America. In addition, Neuren is advancing the pre-clinical development of its second drug candidate NNZ-2591.

Contact:

Dr Richard Treagus, Executive Chairman: rtreagus@neurenpharma.com; +61 417 520 509

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.